ACRO | 提供您關於COVID-19疫苗安全性和免疫原性評估解決方案

ACRO | 提供您關於COVID-19疫苗安全性和免疫原性評估解決方案

2020.10.19

https://files.constantcontact.com/5f3d0cf9401/c9459c89-7166-4bb3-acae-79d28e955688.png

 

Solutions for COVID-19 vaccine safety and immunogenicity evaluation

Researchers around the world are working hard on a vaccine for COVID-19. Up until now, several vaccine candidates have entered into phase III clinical trials. Experts estimate that a fast-tracked vaccine development process could potentially bring a successful candidate to market within one year or even less. In the development of a COVID-19 vaccine, safety and immunogenicity evaluation are indispensable and well-established assays are required for fast and convenient assessment of the vaccine candidates.

Based on advanced technology platform in recombinant protein production, ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation, including recombinant proteins, antibodies and ELISA kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection to accelerate the vaccine development.

Application

>>> Scenario 1: IgG antibody titer detection

>> Recommended products

Cat.No. SPN-C52H9  

Products: SARS-CoV-2 S protein, His Tag, Super stable trimer (MALS & NS-EM verified)

·    The purity, molecular weight and polymeric form were rigorously verified by SDS-PAGE, SEC-MALS and NS-EM.

https://files.constantcontact.com/5f3d0cf9401/d90871af-e3aa-4d2d-933a-03be1fc95e0a.jpg

Fig 1. The purity of SARS-CoV-2 S protein, His Tag, Super stable trimer (Cat. No. SPN-C52H9) was more than 90% verified by SDS-PAGE under reducing (R) condition. The molecular weight was around 550-660 kDa confirmed by SEC-MALS. The particles are similar in size and appearance to SARS-CoV-2 trimers reported in published literature verified by negative stain electron micrography.

·    Bioactivity of binding to anti-SARS-CoV-2 neutralizing antibody was verified by ELISA

https://files.constantcontact.com/5f3d0cf9401/9da5c89c-a932-469a-beaf-9c19d5b3d315.jpg

Fig 2. Immobilized Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 S protein, His Tag, Super stable trimer (Cat. No. SPN-C52H9) with a linear range of 0.3-10 ng/mL

Cat.No. SPD-C82E9  

Products: Biotinylated SARS-CoV-2 (COVID-19) S protein RBD, His,Avitag™ (MALS verified)

·    Bioactivity of binding to anti-SARS-CoV-2 neutralizing antibody was verified by ELISA

https://files.constantcontact.com/5f3d0cf9401/acf0aefe-356f-4bea-8f97-05871508a205.jpg

Fig 3. Immobilized Biotinylated SARS-CoV-2 S protein RBD, His,Avitag (Cat. No. SPD-C82E9) at 1 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Monoclonal Anti-SARS-CoV-S protein RBD Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL

>> Case Study

Pfizer employed ACROBiosystems’ featured biotinylated S protein RBD in the RBD-binding IgG assay during the phase 1/2 research. The interim report showed that the biotinylated S protein RBD from ACROBiosystems (Cat.No. SPD-C82E9) was bound to streptavidin-coated Luminex microspheres.

https://files.constantcontact.com/5f3d0cf9401/2fb32eba-630d-4b56-95d1-c849a79c4e77.png

https://files.constantcontact.com/5f3d0cf9401/20dbb04c-c469-41ff-bb8c-0ee41e0c10dc.png

Reference: Mulligan et al., (2020). Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. medRxiv, doi: http://life.acrobiosystems.cn/e/535472/10-1101-2020-06-30-20142570/2ltqp9b/1014932761?h=ZaZbs5vDDB1xvQSqFnCJ3Y8cvsX-JqYiElZkxBsY_NM

Cat.No. TAS-K002  

Products: Anti-SARS-CoV-2 Antibody IgG Titer Serologic Assay kit (Spike protein RBD)

https://files.constantcontact.com/5f3d0cf9401/d792dfb9-fc26-446d-94c7-aecca58d9987.jpg

Fig 4. Immobilized SARS-CoV-2 S protein RBD at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-SARS-CoV-2 Antibody, Human IgG1 in 1:50 human serum. Detection was performed using HRP-Conjugated Anti-human IgG antibody with sensitivity of 24 ng/mL

>>> Scenario 2: Neutralizing antibody titer detection

>> Recommended products

Cat.No. SPD-C52H3  

Products:SARS-CoV-2 (COVID-19) S protein RBD, His Tag (MALS verified)

·    Bioactivity of binding to anti-SARS-CoV-2 neutralizing antibody was verified by ELISA

https://files.constantcontact.com/5f3d0cf9401/bcebe297-6f66-419b-b313-9d8a490029b7.jpg

Fig 5. Immobilized SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H3) at 1 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) with a linear range of 0.1-3 ng/mL

·    Bioactivity of binding to ACE-2 was verified by ELISA

https://files.constantcontact.com/5f3d0cf9401/f7ff4e0c-bca5-4428-817f-8f0ca28a47de.jpg

Fig 6. Immobilized SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H3) at 1 μg/mL (100 μL/well) can bind Human ACE2, Fc Tag (Cat. No. AC2-H5257) with a linear range of 0.2-3 ng/mL

Cat.No. TAS-K003 

Products: Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Assay kit

https://files.constantcontact.com/5f3d0cf9401/e38c4bbe-8d5f-4c6a-b4c0-b3707723b85a.jpg

Fig 7. Neutralizing titer of Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat.No.SAD-S35) measured by Anti-SARS-CoV-2 neutralizing antibody titer serologic assay kit (Cat. No. TAS-K003).

>>> Scenario 3: Antigen titer detection

>> Recommended products

Cat.No. TAS-K011  

Products: SARS-CoV-2 Spike Protein Titer Assay Kit

https://files.constantcontact.com/5f3d0cf9401/b6a305af-d123-453e-bcfa-e3b78201ec97.jpg

Fig 8. Immobilized Anti-SARS-CoV-2 Spike S1 Antibody at 2 μg/mL (100 μL/well) can bind SARS-CoV-2 Spike Protein. And then add Biotinylated Anti-SARS-CoV-2 Spike S1 Antibody at 1ug/ml. Detection was performed using HRP-conjugated streptavidin with sensitivity of 24 pg/mL

Product List

>> Proteins

https://files.constantcontact.com/5f3d0cf9401/710ef5b3-0073-4725-abbf-a34dc37d1f6a.png

https://files.constantcontact.com/5f3d0cf9401/df851a34-99f3-452d-a2db-be04c368c5b0.png

>> Antibodies

https://files.constantcontact.com/5f3d0cf9401/30b13eb9-deae-464c-9435-37cf090c652f.png

>> Kits

https://files.constantcontact.com/5f3d0cf9401/99dcc190-c3a7-4617-a763-b91a8add1d7c.png

back-Top
open-line

LINE 線上諮詢

亞旭-LINE-QRcode

掃瞄或手機直接點擊條碼

error: Content is protected !!